Hepatitis D Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Hepatitis D Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Hepatitis D Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Hepatitis D Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hepatitis D, historical and forecasted epidemiology as well as the Hepatitis D market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

HDV is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV requires hepatitis B virus (HBV) for its replication. HDV infection occurs as co-infection or as super-infection with HBV.

Currently, no treatment is available for HDV infection specifically. Pegylated interferon-alpha has shown some efficacy, but the sustained virologic response rate (a measure of viral clearance) is low.

Get FREE sample copy at: 

The Hepatitis D market report also covers emerging drugs, current treatment practices, Hepatitis D market share of the individual therapies, current and forecasted Hepatitis D Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Hepatitis D treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Hepatitis D Market Key Facts

  • In the 7MM, the total diagnosed prevalent cases of Hepatitis D Virus (HDV) were 204,976 cases in 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.

  • In EU-5 countries the highest number of diagnosed prevalent cases of Hepatitis D Virus (HDV) was in Germany, followed by Italy and Spain

  • According to the World Health Organization (WHO) estimates, Hepatitis D virus (HDV) affects globally nearly 5% of people who have a chronic infection with hepatitis B virus (HBV).

  • According to the research study of Chen et al. (2019), the global prevalence of HDV is 0.98%, and approximately 10.58% of the global HBsAg carriers are also coinfected with HDV, which means the global burden of HDV infection is approximately 62–72 million individuals.

  • In 2017, the US accounted for 112,673 prevalent cases for Hepatitis D Virus (HDV), which is highest among the 7MM.

Key Benefits of Hepatitis D Market Report

  • Hepatitis D market report provides an in-depth analysis of Hepatitis D Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Hepatitis D market report will help in developing business strategies by understanding the Hepatitis D Market trends & developments, key players, and future market competition that will shape and drive the Hepatitis D market in the upcoming years.

  • The Hepatitis D market report covers Hepatitis D current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Hepatitis D market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Hepatitis D Market

The market size of Hepatitis D Virus (HDV) in the 7MM was found to USD 285.1 million in 2017, which is expected to increase during the forecast period. The growth of the Hepatitis D Virus (HDV) market is expected to be mainly driven by the increase in prevalent pool owing to rise in awareness and WHO initiatives, the anticipated launch of premium price therapies with functional cure, increase in healthcare access with the help of target set by WHO for 2030, increasing affordability and increase in scientific research and interest.

The Hepatitis D market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Hepatitis D market trends by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Hepatitis D market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Hepatitis D Epidemiology

The Hepatitis D epidemiology section covers insights about the historical and current Hepatitis D patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Hepatitis D Drugs Uptake and Key Market Players

The Hepatitis D Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis D market or expected to get launched in the market during the study period. The analysis covers Hepatitis D market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of the Hepatitis D Virus (HDV) market is anticipated to change in the coming years. Some of the key players are globally involved in developing drugs for Hepatitis D Virus (HDV).

Hepatitis D Virus (HDV) Companies:
MYR Pharmaceuticals
Eiger Biopharmaceuticals
Janssen Pharmaceuticals
And many others

Hepatitis D Virus (HDV) therapies covered in the report include:
Peginterferon Lambda
JNJ-73763989 (JNJ-3989)
And many more

Table of Content

1. Key Insights

2. Executive Summary 

3. Hepatitis D Competitive Intelligence Analysis

4. Hepatitis D Market Overview at a Glance

5. Hepatitis D Disease Background and Overview

6. Hepatitis D Patient Journey

7. Hepatitis D Epidemiology and Patient Population

8. Hepatitis D Treatment Algorithm, Current Treatment, and Medical Practices

9. Hepatitis D Unmet Needs

10. Key Endpoints of Hepatitis D Treatment

11. Hepatitis D Marketed Products

12. Hepatitis D Emerging Therapies

13. Hepatitis D Seven Major Market Analysis

14. Attribute Analysis

15. Hepatitis D Market Outlook (7 major markets)

16. Hepatitis D Access and Reimbursement Overview

17. KOL Views on the Hepatitis D Market.

18. Hepatitis D Market Drivers

19. Hepatitis D Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Related Reports By DelveInsight
Hepatitis D Epidemiology Forecast

DelveInsight’s Hepatitis D – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hepatitis D in the 7MM.

Hepatitis D Pipeline Insights
Hepatitis D Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hepatitis D market.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/